146 related articles for article (PubMed ID: 19140396)
1. Urocanate as a potential signaling molecule for bacterial recognition of eukaryotic hosts.
Zhang XX; Ritchie SR; Rainey PB
Cell Mol Life Sci; 2014 Feb; 71(4):541-7. PubMed ID: 24305948
[TBL] [Abstract][Full Text] [Related]
2. Not just an antibiotic target: Exploring the role of type I signal peptidase in bacterial virulence.
Walsh SI; Craney A; Romesberg FE
Bioorg Med Chem; 2016 Dec; 24(24):6370-6378. PubMed ID: 27769673
[TBL] [Abstract][Full Text] [Related]
3. Dismantling the bacterial virulence program.
Alford MA; Pletzer D; Hancock REW
Microb Biotechnol; 2019 May; 12(3):409-413. PubMed ID: 30864265
[TBL] [Abstract][Full Text] [Related]
4. A novel antibacterial strategy for targeting the bacterial methionine biosynthesis pathway.
Bin P; Liu W; Zhang X; Liu B; Zhu G
Int J Antimicrob Agents; 2024 Feb; 63(2):107057. PubMed ID: 38072168
[TBL] [Abstract][Full Text] [Related]
5. VirulentPred 2.0: An improved method for prediction of virulent proteins in bacterial pathogens.
Sharma A; Garg A; Ramana J; Gupta D
Protein Sci; 2023 Dec; 32(12):e4808. PubMed ID: 37872744
[TBL] [Abstract][Full Text] [Related]
6. Editorial: Research implications on microbial virulence factors, resistance, and new therapeutic strategies in the context of future infectious disease therapies.
Dyląg M; Filipić B; Augustyniak D; Milenković MT
Front Cell Infect Microbiol; 2024; 14():1406119. PubMed ID: 38912209
[No Abstract] [Full Text] [Related]
7. Editorial: Novel insights on the role of bacterial membrane proteins in virulence and pathogenesis.
Mohapatra H; Arenas J
Front Cell Infect Microbiol; 2023; 13():1282672. PubMed ID: 37743868
[No Abstract] [Full Text] [Related]
8. Development of Chlamydial Type III Secretion System Inhibitors for Suppression of Acute and Chronic Forms of Chlamydial Infection.
Zigangirova NA; Zayakin ES; Kapotina LN; Kost EA; Didenko LV; Davydova DY; Rumyanceva JP; Gintsburg AL
Acta Naturae; 2012 Apr; 4(2):87-97. PubMed ID: 22880162
[TBL] [Abstract][Full Text] [Related]
9. [The choice of the targets and the search for their inhibitors by means of computer simulation for the development of innovative preparations to treat of chronic bacterial infections].
Kariagina AS; Zigangirova NA; Grishin AV; Davydova DIu; Krivozubov MS; Kirsanov DD; Zaiakin ES
Vestn Ross Akad Med Nauk; 2011; (10):22-8. PubMed ID: 22168035
[TBL] [Abstract][Full Text] [Related]
10. [Target-directed search of anti-virulence drugs].
Zigangirova NA; Fedina ED; Zorina VV; Bortsov PA; Tokarskaia EA; Kariagina AS; Alekseevskiĭ AV; Kraiushkin MM; Zaiakin ES; Iarovenko VN; Gintsburg AL
Zh Mikrobiol Epidemiol Immunobiol; 2009; (4):71-7. PubMed ID: 19715208
[TBL] [Abstract][Full Text] [Related]
11. Anti-virulence Strategies to Target Bacterial Infections.
Mühlen S; Dersch P
Curr Top Microbiol Immunol; 2016; 398():147-183. PubMed ID: 26942418
[TBL] [Abstract][Full Text] [Related]
12. [Type III bacterial secretion system, a promising target for the development of a new generation of antibiotic drugs].
Gintsburg AL; Zigangirova NA; Zorina VV
Vestn Ross Akad Med Nauk; 2008; (10):34-9. PubMed ID: 19140396
[TBL] [Abstract][Full Text] [Related]
13. Novel agents to inhibit microbial virulence and pathogenicity.
Escaich S
Expert Opin Ther Pat; 2010 Oct; 20(10):1401-18. PubMed ID: 20718591
[TBL] [Abstract][Full Text] [Related]
14. The fallacies of hope: will we discover new antibiotics to combat pathogenic bacteria in time?
Vicente M; Hodgson J; Massidda O; Tonjum T; Henriques-Normark B; Ron EZ
FEMS Microbiol Rev; 2006 Nov; 30(6):841-52. PubMed ID: 17064283
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
